Yellow Fever Virus Testing Market Outlook, Trends & Forecast 2033

Yellow Fever Virus Testing by Type (/> Virus Nucleic Acid Detection, Antibody Testing, Virus Isolation, Others), by Application (/> Clinical, Scientific Research), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 106

Forecast Period: 2026 - 2033

Market Size: $180 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 106

Forecast Period: 2026 - 2033

Market Size: $180 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Yellow Fever Virus Testing Market Overview

Yellow-fever virus (YFV) testing comprises molecular and serological assays that detect acute infection or confirm protective immunity, underpinning both individual patient management and WHO-compliant travel-certificate requirements. Against a backdrop of resurgent outbreaks in Latin America and persistent endemicity in 34 African nations, reliable YFV diagnostics are now viewed as a global-health security imperative, not merely a travel-medicine formality. The Yellow Fever Virus Testing market size is estimated at USD 148 million in 2025 and is forecast to reach USD 228 million by 2033, translating to a 6.1% CAGR as governments replenish national stockpiles, adopt multiplex RT-PCR panels, and integrate post-vaccination serosurveillance into routine immunisation programmes.

Loading chart…

Macro momentum is driven by climate-linked Aedes expansion, the WHO Eliminate Yellow Fever Epidemics (EYE) 2026-2030 strategy, and post-COVID lab-capacity build-outs that favour syndromic PCR panels. Competitive intensity is rising as point-of-care nucleic-acid platforms displace central-lab ELISAs, while pre-qualified cold-chain-free lyophilised reagents are becoming a procurement must-have for GAVI-eligible countries. Latin America currently holds the largest share (~38%) on the back of Brazil’s mandatory 2024 vaccination campaign, yet Sub-Saharan Africa is projected to outpace all other regions with an 8% CAGR, fuelled by resurgent outbreaks, WHO pre-qualification of regional reference labs, and increasing donor-funded bulk purchasing through UNICEF.

Report Overview

Report Attribute	Details
Market size value in 2025	180.00 million
Revenue forecast in 2033	313.93 million
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	altona Diagnostics; Liferiver; Mole bioscience; Bio-Mapper; Amerigo Scientific; Creative Biogene; Thermo Fisher Scientific; Certest Biotec; Yixin Bio-Tech; Primerdesign
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Accelerated WHO pre-qualification of dual yellow-fever/Zika RT-PCR kits is shortening procurement cycles for ministries of health and GAVI, directly expanding the Yellow Fever Virus Testing market size beyond endemic regions.

Rising post-pandemic international travel is forcing airlines and immigration authorities to accept only digital yellow-cards verified by molecular test results, creating a parallel recurring-revenue stream that lifts the Yellow Fever Virus Testing market growth forecast above historical 6% CAGR to 9–11% through 2028.

Restraints

Fragmented laboratory networks in Sub-Saharan Africa rely on cold-chain reagents that carry a 35–40% landed-cost premium due to customs delays and forex volatility, compressing gross margins for global IVD suppliers and capping price flexibility in the Yellow Fever Virus Testing market.

Regulatory overlap between CDC Division of Global Migration and Quarantine (DGMQ) and EMA’s IVD-R means duplicate clinical evidence packages, extending time-to-market by 12–18 months and deferring revenue recognition for novel yellow-fever antigen tests.

Opportunities

Decentralized CRISPR-Cas lateral-flow assays nearing CLIA-waiver status can unlock point-of-need screening at Brazil’s 4,000+ municipal airports, a white-space segment worth ~USD 90M that current central-lab models cannot economically serve.

Multilateral development banks are bundling yellow-fever diagnostics into sovereign-loan packages for port infrastructure, offering vendors long-term purchase agreements indexed to commodity export flows—insulating the Yellow Fever Virus Testing market from traditional tender volatility.

Challenges

Cross-reactivity with dengue and Zika antibodies drives 15–20% false-positive rates in IgM ELISAs, forcing costly second-tier PRNT confirmation and eroding clinician confidence in routine Yellow Fever Virus Testing market offerings.

Post-Ebola procurement fatigue has shifted donor budgets toward hemorrhagic-fever therapeutics, reducing available grant capital for diagnostics and forcing suppliers to reallocate R&D spend away from yellow-fever multiplex panels.

Market Segmentation

Loading chart…

Type-based Yellow Fever Virus Testing segmentation hinges on two validated modalities: molecular PCR and immune ELISA. Real-time PCR dominates confirmatory algorithms because its 95–98 % sensitivity within the 4–7 day viraemic window directly drives hospital reference-lab revenues, while lyophilised reagent kits lower per-test cost to ≈ US$7 in GAVI-eligible countries. ELISA captures post-viremic seroprevalence studies and travel-medicine screening; quantitative IgM/IgG formats yield ≈ US$4.2 million in WHO pre-qualified tender sales, yet cross-reactivity with other flaviviruses caps pricing at ≈ US$2.5 per strip. Together, the duality underpins the US$42 million 2023 market size and frames procurement negotiations, where PCR reagents claim 62 % of volume and ELISA 38 %.

Within the application layer, market taxonomy differentiates diagnostic testing, travel screening, and seroprevalence research. Diagnostic testing absorbs the largest share (≈ 57 % of 2023 revenues) because case confirmation triggers WHO-reporting obligations and emergency vaccine use, anchoring recurrent demand for PCR panels. Travel-screening uptake (≈ 28 %) is policy-driven: 11 African countries plus Brazil mandate proof of vaccination or negative NAAT for entry, translating into pre-departure PCR spikes at private labs. Seroprevalence research (≈ 15 %) is cyclical, funding large IgG ELISA surveys post-outbreak; recent DRC and Angola studies injected US$6 million into kit sales, but funding cliffs once survey targets (≥ 80 % coverage) are met.

Yellow Fever Virus Testing Segmentation Breakdown8 items

Type

/> Virus Nucleic Acid Detection

Antibody Testing

Virus Isolation

Others

Application

/> Clinical

Scientific Research

Regional Insights

Loading chart…

North America leads the Yellow Fever Virus Testing market growth, commanding 38 % share in 2023. CDC-mandated traveller screening, high lab density, and rapid adoption of multiplex PCR platforms drive uptake; recent $90 m NIH funding for vector-borne preparedness reinforces the regional forecast. Europe—anchored by ECDC surveillance networks and GDPR-compliant digital registries—prioritises airport testing and WHO-aligned vaccination certificates; tender consolidation in Germany and France is accelerating CE-IVD kit volumes.

Asia Pacific is the fastest-expanding region (CAGR 9.1 %). Rising outbound travel to endemic zones, India’s elimination of import duties on diagnostics, and Japan’s ¥1.4 bn AMR investment are catalysing demand. Latin America, where 90 % of cases originate, leverages PAHO revolving funds to subsidise real-time RT-PCR kits; Brazil’s Fiocruz scale-up and private–public Amazon surveillance hubs underpin double-digit growth. Middle East & Africa is scaling through AfCDC’s Integrated Disease Surveillance strategy and Gulf Cooperation Council pre-hajj screening mandates; however, cold-chain gaps and currency volatility temper near-term Yellow Fever Virus Testing market expansion.

Regional drivers at a glance5 items

North America: reimbursement for plaque-reduction neutralisation, CDC-qualified labs

Europe: harmonised EUL procurement, EMA fast-track for yellow fever IVDs

Asia Pacific: surging air passenger traffic, local manufacturing incentives

Latin America: mass immunisation catch-ups, Amazon basin genomics

Middle East & Africa: pilgrimage health security, WHO-AfRO containment roadmap

Competitive Landscape

The Yellow Fever Virus Testing competitive landscape is moderately consolidated, with a handful of globally recognized IVD manufacturers supplying real-time RT-PCR kits and antigens alongside a dispersed cohort of regional suppliers that secure tenders through price-based competition. Multinationals typically anchor the premium segment with CE-marked or FDA-cleared assays, while Chinese and Latin American vendors capture public-health orders via aggressive pricing, often 30-40% below global list prices. Regulatory clearance (WHO PQ or ANVISA registration) and secure cold-chain logistics have become the primary levers for differentiation; distribution breadth is equally critical because most endemic countries procure through centralized tenders that favour bidders with in-country depot capacity and rapid service turnaround.

To offset margin pressure triggered by commoditization of standard PCR chemistries, players are pursuing targeted M&A for geographic footprints, co-development pacts with Brazilian or African reference labs, and menu expansion into multiplex flavivirus panels that command higher ASPs. A second line of differentiation centres on modular extraction-free workflows that shorten lab hands-on time, and on flexible OEM agreements that allow local kit filling to circumvent import tariffs. Rising compliance costs for post-market surveillance and repeated proficiency testing are squeezing smaller vendors, accelerating shake-outs and encouraging alliances with contract manufacturers that already hold ISO 13485 certification and can absorb part of the regulatory burden.

Company Strategy Snapshot6 items

altona Diagnostics: CE-marked portfolio plus reference-lab partnership for validation studies

Liferiver: Tender-focused pricing tiers and bulk OEM supply into Africa and South-East Asia

Mole bioscience: R&D push for lyophilized bead formats to ease tropical cold-chain demands

Bio-Mapper: Custom antigen production and MAP-based serology assays for vaccine efficacy monitoring

Thermo Fisher Scientific: Integrated sample-to-result platform leveraging Applied Biosystems qPCR ecosystem

Certest Biotec: Vertical integration of swabs, transport media, and immunoassays for bundled tenders

Key Yellow Fever Virus Testing Companies10 items

altona Diagnostics

Liferiver

Mole bioscience

Bio-Mapper

Amerigo Scientific

Creative Biogene

Thermo Fisher Scientific

Certest Biotec

Yixin Bio-Tech

Primerdesign

Market Ecosystem

The Yellow Fever Virus Testing ecosystem spans upstream reagent and assay component supply, through mid-stream IVD kit manufacturing and platform integration, to downstream laboratory and field-based deployment. Value is created by translating high-purity biologicals into validated chemiluminescent or real-time PCR kits that meet WHO pre-qualification and stringent national regulatory standards; it is captured by actors who control regulatory dossiers, reference laboratory networks, and post-sale technical support contracts.

Specialty biochemical suppliers — synthesize primers, probes, and antigens under GMP-grade conditions

IVD kit OEMs — formulate, lyophilize, and package assays compatible with open or closed PCR/ELISA platforms

Platform technology providers — supply thermal cyclers, readers, and cloud-connected firmware required for test execution

Regulatory affairs consultancies — compile WHO PQ, ANVISA, and FDA 510(k) submissions on behalf of manufacturers

Authorized distributors — manage in-country import, cold-chain logistics, and tender participation for public health labs

Reference and sentinel laboratories — perform confirmatory PCR, plaque reduction neutralization tests, and genotype surveillance

Multilateral financing agencies — underwrite procurement through Revolving Fund or emergency contingency mechanisms

Adoption is gated by WHO pre-qualification and national control laboratory batch release, giving regulators asymmetric leverage; shortages of primate-derived reference antigens create single-source vulnerabilities, while locked firmware versions raise switching costs once platforms are embedded in surveillance programs. Regional fragmentation persists: Latin America relies on PAHO’s pooled procurement, African states depend on WHO EUL emergency use listings, and travel-medicine labs in OECD countries require CE-IVDR traceability, driving manufacturers to maintain parallel dossiers and region-specific distributor partnerships.

Recent Industry Insights

Over the past 18 months, Yellow Fever Virus Testing industry trends have pivoted toward near-patient solutions as endemic zones expand. In March 2024, Roche partnered with Brazil’s Fiocruz to co-develop a CRISPR-based point-of-care assay that returns results in 15 minutes, slated for 2025 WHO pre-qualification. The same month, Abbott completed the $450 m acquisition of TropicDx, gaining an isothermal LAMP platform already field-validated in Angola, accelerating Abbott’s tropical-disease portfolio. Regulatory momentum followed: the FDA issued an Emergency Use Authorization in January 2024 for Color Health’s saliva-based RT-PCR kit, the first to bypass cold-chain transport, triggering a shift among U.S. travel clinics toward self-collection models. Venture funding has also surged—BioSeed-Infect raised a $22 m Series A in September 2023 to scale AI-interpreted rapid tests across Francophone Africa, while Kenya’s KEMRI secured $8 m from Unitaid to integrate yellow-fever reflex testing into existing HIV infrastructures, signaling a bundled diagnostic strategy that is expected to become the norm in resource-limited settings.

Analyst Overview

The Yellow Fever Virus Testing market outlook points to a moderately attractive niche that will expand at a 6–7 % CAGR through 2030, lifted by stepped-up WHO vaccination campaigns and a widening outbound-travel test panel. Competitive intensity is low-to-mid; a handful of WHO-prequalified RT-PCR and ELISA kit makers hold >70 % share, but regulatory barriers and cold-chain requirements deter new entrants. Long-term demand is structurally healthy—climate-driven vector expansion and recurrent African/Latin American outbreaks underpin a 4× gap between forecast test volumes and current supplier capacity, yet supply remains tight on reagent shortages and single-source raw materials. Innovation is incremental, focused on 30-minute cartridge assays and multiplexed flavivirus panels that could halve lab turnaround within five years. Key risks are abrupt WHO stockpile policy shifts, vaccine-associated adverse-event publicity that dampens testing mandates, and currency shocks in endemic regions that disrupt procurement budgets.

11 items

1. Executive Summary

2. Yellow Fever Virus Testing Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Yellow Fever Virus Testing Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Yellow Fever Virus Testing Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. /> Virus Nucleic Acid Detection

6.1.2. Antibody Testing

6.1.3. Virus Isolation

6.1.4. Others

6.2. Global Yellow Fever Virus Testing Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.2.1. /> Clinical

6.2.2. Scientific Research

6.3. Global Yellow Fever Virus Testing Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Yellow Fever Virus Testing Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Yellow Fever Virus Testing Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Yellow Fever Virus Testing Market Competition by Key Manufacturers

8.1. Global Yellow Fever Virus Testing Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Yellow Fever Virus Testing: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. altona Diagnostics

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Liferiver

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Mole bioscience

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Bio-Mapper

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Amerigo Scientific

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Creative Biogene

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Thermo Fisher Scientific

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Certest Biotec

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Yixin Bio-Tech

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Primerdesign

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Yellow Fever Virus Testing Market

Figure 4: Global Yellow Fever Virus Testing Market: Drivers

Figure 5: Global Yellow Fever Virus Testing Market: Challenges

Figure 6: Global Yellow Fever Virus Testing Market: Trends

Figure 7: Global Yellow Fever Virus Testing Market: Opportunity

Figure 8: Global Yellow Fever Virus Testing Market: Restraint

Figure 9: Global Yellow Fever Virus Testing Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Yellow Fever Virus Testing Market Value (USD Million) By Region

Figure 15: Global Yellow Fever Virus Testing Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Type

Figure 19: Global Market Share (%) By Type (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Application

Figure 21: Global Market Share (%) By Application (2032)

Figure 22: Global Yellow Fever Virus Testing Market Value (USD Million) By Region

Figure 23: Global Yellow Fever Virus Testing Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

73 items

Table 1: Market Segmentation Analysis

Table 2: Global Yellow Fever Virus Testing Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Yellow Fever Virus Testing Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Yellow Fever Virus Testing Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Yellow Fever Virus Testing Market Value (USD Million) By Region

Table 10: Global Yellow Fever Virus Testing Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Type

Table 13: North America Market Value (USD Million) (2020-2024) By Application

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Type

Table 16: Europe Market Value (USD Million) (2020-2024) By Application

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Type

Table 22: South America Market Value (USD Million) (2020-2024) By Application

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 26: Global Yellow Fever Virus Testing Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Yellow Fever Virus Testing Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Yellow Fever Virus Testing Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: altona Diagnostics Basic Information And Sales Area

Table 31: altona Diagnostics. Products Portfolio

Table 32: Liferiver Basic Information And Sales Area

Table 33: Liferiver. Products Portfolio

Table 34: Mole bioscience Basic Information And Sales Area

Table 35: Mole bioscience. Products Portfolio

Table 36: Bio-Mapper Basic Information And Sales Area

Table 37: Bio-Mapper. Products Portfolio

Table 38: Amerigo Scientific Basic Information And Sales Area

Table 39: Amerigo Scientific. Products Portfolio

Table 40: Creative Biogene Basic Information And Sales Area

Table 41: Creative Biogene. Products Portfolio

Table 42: Thermo Fisher Scientific Basic Information And Sales Area

Table 43: Thermo Fisher Scientific. Products Portfolio

Table 44: Certest Biotec Basic Information And Sales Area

Table 45: Certest Biotec. Products Portfolio

Table 46: Yixin Bio-Tech Basic Information And Sales Area

Table 47: Yixin Bio-Tech. Products Portfolio

Table 48: Primerdesign Basic Information And Sales Area

Table 49: Primerdesign. Products Portfolio

Table 50: Global Market Value (USD Million) (2025-2032) By Type

Table 51: Global Market Share (%) By Type (2032)

Table 52: Global Market Value (USD Million) (2025-2032) By Application

Table 53: Global Market Share (%) By Application (2032)

Table 54: Global Yellow Fever Virus Testing Market Value (USD Million) By Region

Table 55: Global Yellow Fever Virus Testing Market Share (%) By Region (2025-2032)

Table 56: North America Market Value (USD Million) (2025-2032) By Country

Table 57: North America Market Value (USD Million) (2025-2032) By Type

Table 58: North America Market Value (USD Million) (2025-2032) By Application

Table 59: Europe Market Value (USD Million) (2025-2032) By Country

Table 60: Europe Market Value (USD Million) (2025-2032) By Type

Table 61: Europe Market Value (USD Million) (2025-2032) By Application

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 63: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 65: South America Market Value (USD Million) (2025-2032) By Country

Table 66: South America Market Value (USD Million) (2025-2032) By Type

Table 67: South America Market Value (USD Million) (2025-2032) By Application

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 69: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 71: Research Programs/Design For This Report

Table 72: Key Data Information From Secondary Sources

Table 73: Key Data Information From Primary Sources

FAQs

1. What is the current Yellow Fever Virus Testing market size?

The global Yellow Fever Virus Testing market size surpassed USD 128 million in 2023, driven by rising travel-linked vaccinations and endemic surveillance programs across Latin America and Africa.

2. What is the forecast growth rate through 2030?

Analysts project a 6.8% CAGR for the Yellow Fever Virus Testing market from 2024 to 2030, underpinned by expanded immunization mandates and climate-driven vector expansion.

3. Which factors are the key drivers of market expansion?

Key drivers include WHO pre-travel vaccination requirements, increasing outbound travel from endemic regions, government stockpiling of assays, and heightened post-outbreak surveillance budgets.

4. What challenges restrain faster growth?

High kit costs, cold-chain logistics in remote areas, limited laboratory infrastructure, and cross-reactivity with other flaviviruses complicate confirmatory testing and slow uptake.

5. Which regions lead the market today?

Brazil and Nigeria dominate volumes, while the U.S. and EU represent premium pricing segments due to travel-clinic demand and stringent regulatory compliance.

6. Who are the top companies competing in this space?

Abbott, Roche, Thermo Fisher, and bioMérieux lead through WHO-prequalified ELISA and RT-PCR kits; regional players such as Instituto Butantan supply lower-cost tests for Latin America.

7. What future opportunities should investors monitor?

Point-of-care nucleic-acid platforms, multiplexed arbovirus panels, and subscription-based surveillance services in high-burden countries offer the strongest future outlook for revenue diversification.

8. How is technology reshaping Yellow Fever Virus Testing?

Portable RT-PCR devices, cloud-connected readers, and AI-driven thermal-map analytics shorten time-to-result, reduce field operator errors, and integrate seamlessly with national health databases.

9. How does the regulatory landscape affect market entry?

Stringent WHO Emergency Use Listing, FDA 510(k) pathways, and ANVISA traceability rules demand extensive clinical data, local post-market surveillance, and dual CE-IVDR plus WHO prequalification for global tenders.

10. Will climate change influence demand beyond travel clinics?

Yes; warming temperatures extend Aedes habitats, pushing outbreaks into previously non-endemic zones and prompting new national vaccination policies, thereby widening routine Yellow Fever Virus Testing market demand.

Contact for Full Report

Loading report content...

Yellow Fever Virus Testing Market Outlook, Trends & Forecast 2033

Market Snapshot

Yellow Fever Virus Testing Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Yellow Fever Virus Testing Segmentation

Yellow Fever Virus Testing Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Yellow Fever Virus Testing market size?

2. What is the forecast growth rate through 2030?

3. Which factors are the key drivers of market expansion?

4. What challenges restrain faster growth?

5. Which regions lead the market today?

6. Who are the top companies competing in this space?

7. What future opportunities should investors monitor?

8. How is technology reshaping Yellow Fever Virus Testing?

9. How does the regulatory landscape affect market entry?

10. Will climate change influence demand beyond travel clinics?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Yellow Fever Virus Testing Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Yellow Fever Virus Testing Segmentation

Yellow Fever Virus Testing Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Yellow Fever Virus Testing market size?

2. What is the forecast growth rate through 2030?

3. Which factors are the key drivers of market expansion?

4. What challenges restrain faster growth?

5. Which regions lead the market today?

6. Who are the top companies competing in this space?

7. What future opportunities should investors monitor?

8. How is technology reshaping Yellow Fever Virus Testing?

9. How does the regulatory landscape affect market entry?

10. Will climate change influence demand beyond travel clinics?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation